Boxer Capital Management LLC bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 671,358 shares of the company's stock, valued at approximately $15,106,000. Enliven Therapeutics makes up approximately 1.3% of Boxer Capital Management LLC's portfolio, making the stock its 23rd largest position. Boxer Capital Management LLC owned about 1.37% of Enliven Therapeutics as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of the business. Northern Trust Corp grew its position in Enliven Therapeutics by 8.9% in the fourth quarter. Northern Trust Corp now owns 331,500 shares of the company's stock valued at $7,459,000 after acquiring an additional 27,104 shares during the last quarter. Artia Global Partners LP purchased a new stake in shares of Enliven Therapeutics during the 4th quarter worth approximately $2,315,000. Lord Abbett & CO. LLC grew its position in shares of Enliven Therapeutics by 20.3% in the fourth quarter. Lord Abbett & CO. LLC now owns 386,211 shares of the company's stock valued at $8,690,000 after purchasing an additional 65,156 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Enliven Therapeutics by 17.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company's stock valued at $307,000 after acquiring an additional 1,980 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after purchasing an additional 1,114 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.
Insider Buying and Selling at Enliven Therapeutics
In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the company's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $21.44, for a total transaction of $142,940.48. Following the completion of the transaction, the chief operating officer now owns 323,310 shares of the company's stock, valued at $6,931,766.40. This represents a 2.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $18.69, for a total transaction of $60,742.50. Following the transaction, the chief financial officer now owns 23,000 shares in the company, valued at approximately $429,870. The trade was a 12.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 66,751 shares of company stock valued at $1,331,288. Corporate insiders own 29.20% of the company's stock.
Enliven Therapeutics Stock Up 3.3 %
Shares of NASDAQ ELVN traded up $0.66 during trading on Friday, hitting $20.51. The company had a trading volume of 221,177 shares, compared to its average volume of 259,995. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -10.79 and a beta of 1.07. The stock has a fifty day simple moving average of $19.17 and a two-hundred day simple moving average of $22.38.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. On average, analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lifted their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research note on Friday, March 21st.
Check Out Our Latest Research Report on Enliven Therapeutics
About Enliven Therapeutics
(
Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
See Also
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
